Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Apr 16, 2014 11:00 AM - Apr 16, 2014 12:30 PM

(Eastern Standard Time)

Online

Seven-Part Series on Pediatric Drug Development - Part 1: Overall Challenge: The Vision of Better Medicines for Children

Speakers

Klaus  Rose, MD, MS

Klaus Rose, MD, MS

Chief Executive Officer, klausrose Consulting, Switzerland

Klaus Rose, a German MD with postgraduate degrees in General & Pharmaceutical Medicine, was 20 years with Big Pharma. In 2001, he became Global Head Pediatrics at Novartis & 2005 at Roche ; CEO of klausrose Consulting since 2011. He advises on pediatric drug development and FDA/EMA pediatric requirements. Private interests: languages, classical guitar, cooking, wine & gardening

Stephen P. Spielberg, MD, PhD

Stephen P. Spielberg, MD, PhD

Editor-in-Chief, DIA, United States

Dr. Spielberg is Editor-in-Chief of DIA Publications. He has served in: academic medicine (pediatrics and pharmacology), and Dean of Dartmouth Medical School; in the pharmaceutical industry; and most recently as Deputy Commissioner for Medical Products and Tobacco at the US FDA.

Philip D. Walson, MD

Philip D. Walson, MD

Visiting Professor, Dept. Clinical Chemistry, University Medical Center Goettingen, Germany

AB-Chemistry-U.of CalifBerkeley MD-Univ.California,San Francisco (UCSF) PedsU.Chicago ClinPharmacology Fellowship UCSF Assist/Assoc.Prof Peds, Pharmacol. Pharmacy,U.Arizona 1973-81 Prof. Peds,Pharmacol & Pharmacy,the Ohio State Univ.1981-2000 ProfPedsPharmacol &Pharmacy-Univ Cincinnati 2000-2008

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.